JP2015522018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522018A5 JP2015522018A5 JP2015520304A JP2015520304A JP2015522018A5 JP 2015522018 A5 JP2015522018 A5 JP 2015522018A5 JP 2015520304 A JP2015520304 A JP 2015520304A JP 2015520304 A JP2015520304 A JP 2015520304A JP 2015522018 A5 JP2015522018 A5 JP 2015522018A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound according
- acceptable salt
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665951P | 2012-06-29 | 2012-06-29 | |
| US61/665,951 | 2012-06-29 | ||
| US201361779099P | 2013-03-13 | 2013-03-13 | |
| US61/779,099 | 2013-03-13 | ||
| PCT/US2013/046684 WO2014004229A1 (fr) | 2012-06-29 | 2013-06-20 | Composés phénoxyéthyl pipéridine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522018A JP2015522018A (ja) | 2015-08-03 |
| JP2015522018A5 true JP2015522018A5 (fr) | 2016-08-04 |
| JP6127136B2 JP6127136B2 (ja) | 2017-05-10 |
Family
ID=48746666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520304A Active JP6127136B2 (ja) | 2012-06-29 | 2013-06-20 | フェノキシエチルピペリジン化合物 |
Country Status (43)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| AU2014366361B2 (en) * | 2013-12-17 | 2017-04-20 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| DK3625228T3 (da) | 2017-05-18 | 2021-10-11 | Idorsia Pharmaceuticals Ltd | Pyrimidinderivater som pge2-receptormodulatorer |
| CA3063788A1 (fr) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Derives de pyrimidine |
| WO2018210987A1 (fr) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Dérivés de benzofurane et de benzothiophène utilisés en tant que modulateurs du récepteur pge2 |
| UA124748C2 (uk) | 2017-05-18 | 2021-11-10 | Ідорсія Фармасьютікалз Лтд | N-заміщені індольні похідні |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| US20220064113A1 (en) * | 2019-01-22 | 2022-03-03 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| JPWO2022102731A1 (fr) | 2020-11-13 | 2022-05-19 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| AU2003207900A1 (en) * | 2002-03-18 | 2003-09-29 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| JP2006515015A (ja) * | 2003-01-10 | 2006-05-18 | エフ．ホフマン−ラ ロシュ アーゲー | プロスタグランジンアゴニストとしての２−ピペリドン誘導体 |
| WO2005021508A1 (fr) | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2 |
| US20050105732A1 (en) | 2003-11-17 | 2005-05-19 | Hutchings George T. | Systems and methods for delivering pre-encrypted content to a subscriber terminal |
| EP1756043B1 (fr) | 2004-05-04 | 2009-07-01 | RaQualia Pharma Inc | Composes aryl- ou heteroarylamides ortho-substitues |
| CA2565813C (fr) * | 2004-05-04 | 2010-10-26 | Pfizer Inc. | Composes methylaryl- ou heteroarylamides substitues |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| EP2013169B1 (fr) | 2006-04-24 | 2012-08-22 | Merck Canada Inc. | Dérivés d'indolamide comme antagonistes du récepteur ep4 |
| JP5183628B2 (ja) | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体 |
| WO2008092860A1 (fr) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Dérivés bicycliques comme agonistes de ep4 |
| PT2565191E (pt) * | 2008-05-14 | 2014-12-04 | Astellas Pharma Inc | Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética |
| JP5536773B2 (ja) | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
| EP2538978B1 (fr) * | 2010-02-22 | 2016-09-07 | RaQualia Pharma Inc. | Utilisation d'un antagoniste du récepteur ep4 dans le traitement de la dermatite de contact allergique et du psoriasis |
| AU2011305872B2 (en) * | 2010-09-21 | 2015-03-26 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| PL2729445T3 (pl) | 2011-07-04 | 2016-04-29 | Rottapharm Biotech Srl | Cykliczne pochodne aminowe jako antagoniści receptora EP4 |
| EP2729141B1 (fr) * | 2011-07-04 | 2015-12-09 | Rottapharm Biotech S.r.l. | Dérivés aminés cycliques en tant qu'agonistes du récepteur ep4 |
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
-
2013
- 2013-06-13 JO JOP/2013/0177A patent/JO3296B1/ar active
- 2013-06-13 AR ARP130102076 patent/AR091429A1/es active IP Right Grant
- 2013-06-14 TW TW102121220A patent/TWI599561B/zh active
- 2013-06-20 JP JP2015520304A patent/JP6127136B2/ja active Active
- 2013-06-20 MA MA37686A patent/MA37686B1/fr unknown
- 2013-06-20 RS RS20171039A patent/RS56452B1/sr unknown
- 2013-06-20 EA EA201492255A patent/EA024392B1/ru not_active IP Right Cessation
- 2013-06-20 ES ES13734248.1T patent/ES2644812T3/es active Active
- 2013-06-20 WO PCT/US2013/046684 patent/WO2014004229A1/fr active Application Filing
- 2013-06-20 ME MEP-2017-223A patent/ME02840B/fr unknown
- 2013-06-20 KR KR1020147036137A patent/KR101653476B1/ko active IP Right Grant
- 2013-06-20 PE PE2014002532A patent/PE20150182A1/es active IP Right Grant
- 2013-06-20 LT LTEP13734248.1T patent/LT2867207T/lt unknown
- 2013-06-20 BR BR112014031616-3A patent/BR112014031616B1/pt active IP Right Grant
- 2013-06-20 UA UAA201413598A patent/UA114325C2/uk unknown
- 2013-06-20 DK DK13734248.1T patent/DK2867207T3/en active
- 2013-06-20 MX MX2014015953A patent/MX345324B/es active IP Right Grant
- 2013-06-20 EP EP13734248.1A patent/EP2867207B1/fr active Active
- 2013-06-20 NZ NZ701933A patent/NZ701933A/en unknown
- 2013-06-20 AP AP2014008164A patent/AP2014008164A0/xx unknown
- 2013-06-20 CA CA2875569A patent/CA2875569C/fr active Active
- 2013-06-20 HU HUE13734248A patent/HUE034425T2/en unknown
- 2013-06-20 PT PT137342481T patent/PT2867207T/pt unknown
- 2013-06-20 PL PL13734248T patent/PL2867207T3/pl unknown
- 2013-06-20 US US13/922,278 patent/US8962659B2/en active Active
- 2013-06-20 SI SI201330755T patent/SI2867207T1/sl unknown
- 2013-06-20 CN CN201380034168.8A patent/CN104411684B/zh active Active
- 2013-06-20 AU AU2013280875A patent/AU2013280875B2/en active Active
- 2013-06-20 MY MYPI2014703971A patent/MY173878A/en unknown
- 2013-06-20 SG SG11201408641UA patent/SG11201408641UA/en unknown
-
2014
- 2014-11-24 ZA ZA2014/08632A patent/ZA201408632B/en unknown
- 2014-11-27 CO CO14261550A patent/CO7151507A2/es unknown
- 2014-11-28 TN TN2014000501A patent/TN2014000501A1/fr unknown
- 2014-12-03 CR CR20140553A patent/CR20140553A/es unknown
- 2014-12-11 IL IL236219A patent/IL236219A/en active IP Right Grant
- 2014-12-17 GT GT201400288A patent/GT201400288A/es unknown
- 2014-12-17 DO DO2014000287A patent/DOP2014000287A/es unknown
- 2014-12-26 CL CL2014003535A patent/CL2014003535A1/es unknown
- 2014-12-29 EC ECIEPI201433267A patent/ECSP14033267A/es unknown
-
2015
- 2015-01-05 PH PH12015500009A patent/PH12015500009A1/en unknown
- 2015-01-13 US US14/595,350 patent/US9402838B2/en active Active
- 2015-05-07 HK HK15104361.6A patent/HK1203937A1/xx not_active IP Right Cessation
-
2017
- 2017-09-15 CY CY20171100979T patent/CY1119425T1/el unknown
- 2017-10-09 HR HRP20171515TT patent/HRP20171515T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522018A5 (fr) | ||
| JP2016525102A5 (fr) | ||
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| JP2016508134A5 (fr) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2016536286A5 (fr) | ||
| JP2016527217A5 (fr) | ||
| JP2015522589A5 (fr) | ||
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| SI2932970T1 (en) | Antiviral therapy | |
| JP2016528301A5 (fr) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2019515908A5 (fr) | ||
| JP2016522254A5 (fr) | ||
| JP2014502641A5 (fr) | ||
| JP2015532296A5 (fr) | ||
| JP2016539157A5 (fr) | ||
| JP2020512337A5 (fr) | ||
| JP2019505529A5 (fr) | ||
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| RU2017103656A (ru) | Производные изоиндолинона, полезные в качестве противовирусных средств | |
| JP2015516419A5 (fr) |